Successful treatment of epilepsia partialis continua with perampanel: two pediatric cases

Ali Mir1, Montaha Almudhry1, Fouad Al-Ghamdi1

  • 1Department of Pediatric Neurology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Insights

Epilepsia partialis continua (EPC) is a difficult-to-treat epilepsy. Perampanel successfully treated EPC in two pediatric patients with rare underlying conditions, offering a new therapeutic option.

Area of Science:

  • Neurology
  • Pediatric Neurology
  • Epileptology

Background:

  • Epilepsia partialis continua (EPC) is a severe form of focal motor status epilepticus.
  • EPC presents diagnostic and therapeutic challenges, often proving drug-resistant.
  • Current treatment guidelines for EPC are limited, necessitating exploration of novel therapies.

Observation:

  • Two pediatric cases of EPC, one with neuronal ceroid lipofuscinosis (NCL) and another with POLG-related mitochondrial disease, were reported.
  • Both patients exhibited persistent focal motor seizures refractory to multiple antiepileptic drugs (AEDs).
  • Perampanel was initiated in both cases, leading to rapid cessation of EPC episodes.

Findings:

  • Perampanel demonstrated rapid and sustained efficacy in resolving EPC in both pediatric patients.
  • The treatment was well-tolerated, with significant improvement observed within three days of initiation.
  • Both patients maintained seizure control for approximately five months post-treatment.

Implications:

  • Perampanel represents a promising therapeutic option for drug-resistant EPC, particularly in pediatric cases with rare etiologies.
  • The unique mechanism of action of perampanel warrants further investigation for EPC management.
  • This case series contributes valuable evidence for the clinical utility of perampanel in challenging epilepsy syndromes.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
781
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
652
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
889
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
574
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
357